Previous close | 153.43 |
Open | 153.79 |
Bid | 155.16 x 800 |
Ask | 155.05 x 900 |
Day's range | 153.24 - 155.19 |
52-week range | 150.11 - 186.69 |
Volume | |
Avg. volume | 8,242,203 |
Market cap | 483.575B |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | 22.79 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 4.52 (2.95%) |
Ex-dividend date | 17 Feb 2023 |
1y target est | N/A |
Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE) as opportunities that especially stand out. Prosper Junior Bakiny (Axsome Therapeutics): Last year, Axsome Therapeutics' share price doubled, partly due to the FDA approving its depression medicine Auvelity for use. The company's stock is down by 19% since the start of the year.
(Reuters) -A Johnson & Johnson company cannot delay a court order dismissing its bankruptcy, a U.S. court said on Friday, despite the company's planned Supreme Court appeal to use bankruptcy to resolve tens of thousands of lawsuits over its talc products. J&J sought to use the bankruptcy of its subsidiary company, LTL Management, to halt more than 38,000 lawsuits alleging the company's Baby Powder and other talc products are contaminated with asbestos. J&J maintains its consumer talc products are safe and asbestos-free.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.